PMID: 9534106Apr 16, 1998Paper

Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial

Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension
Piero Ruggenenti, G Remuzzi

Abstract

Microalbuminuria is an early marker of diabetic nephropathy, and its prevention can be considered to be the primary prevention of diabetic nephropathy. Angiotensin converting enzyme inhibitors and non-dihydropyridinic calcium antagonists have specific renoprotective properties in diabetes, and preliminary evidence is available that their combination can delay the onset and limit the progression of nephropathy in experimental diabetes more effectively than either of the two agents alone. The Bergamo Nephrologic Diabetes Complication Trial is a prospective, randomized, double-blind, parallel-group study aimed at evaluating the possibility of preventing the onset of nephropathy in 2400 hypertensive non-insulin-dependent diabetes mellitus patients who have a normal albumin excretion rate. During phase A of the study, patients will be randomized to one of the following treatments for 3 years: a non-dihydropyridinic calcium antagonist (slow-release verapamil 240 mg/day), an angiotensin converting enzyme inhibitor (trandolapril 2 mg/day), the combination of these drugs (verapamil 180 mg/day plus trandolapril 2 mg/day) and placebo. Other antihypertensive agents will be allowed in order to achieve and maintain systolic and diastolic blo...Continue Reading

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.